{"id":61949,"date":"2025-09-30T16:06:45","date_gmt":"2025-09-30T14:06:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/"},"modified":"2025-09-30T16:06:45","modified_gmt":"2025-09-30T14:06:45","slug":"reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/","title":{"rendered":"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors"},"content":{"rendered":"
\n

HAYWARD, Calif.–(BUSINESS WIRE)–#BGRT<\/a>—RefleXion Medical<\/a>, an external\u2011beam theranostic oncology company, today announced first results from the PREMIER Registry (NCT05406167<\/a>) evaluating its SCINTIX\u00ae<\/span> biology-guided radiotherapy, or BgRT, platform in patients with lung and bone tumors. The findings, presented at the 2025 ASTRO Annual Meeting, showed local control of 100 percent at nine months post-treatment with no reported Grade 2 or higher adverse events. The data represent the first prospective, multi-institutional evidence of SCINTIX therapy\u2019s clinical impact.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\n\u201cThe PREMIER Registry findings mark a milestone for our field,\u201d said Sean Shirvani, M.D., MPH, chief medical officer at RefleXion. \u201cWe are beginning to see the clinical translation of a technology that can autonomously guide radiation based on real-time biology. Achieving 100% local control in both lung and bone tumors with imaging up to nine months after treatment, without significant toxicity, represents an important step forward in expanding the reach of radiotherapy for patients with advanced cancer.\u201d<\/p>\n

\nBy Feb. 25, 2025, five cancer centers had enrolled 45 patients in the registry, with 28 providing follow-up imaging for analysis. Fifteen patients were treated for lung tumors, including early-stage and metastatic disease, and 13 for bone metastases. The median patient age was 69.5 years, with 39% female.<\/p>\n

\nAcross 39 follow-up scans, investigators reported a local control rate \u2013 defined as complete response (CR), partial response (PR), or stable disease (SD) \u2013 of 100% across available follow-up imaging. Tumor response rates (CR+PR) were 41% overall, including 47% for bone metastases and 35% for lung tumors. No Grade 2 or higher treatment-related adverse events were observed.<\/p>\n

\nRefleXion plans to expand registry enrollment and continue long-term follow-up to strengthen the dataset and evaluate correlations between treatment parameters, imaging metrics and patient outcomes.<\/p>\n

\nThese early results underscore RefleXion\u2019s goal of establishing SCINTIX<\/a> therapy as a first-in-class treatment option for both localized and metastatic disease. As the registry grows, the company expects the evidence to further support BgRT\u2019s integration into routine cancer care.<\/p>\n

\nRefleXion (booth #1433) is also presenting early results characterizing performance of its future, next-generation platform1<\/sup> that offers a 20-fold increase in PET sensitivity, which may increase patient eligibility for SCINTIX therapy. Presentations will be held every 30 minutes in the RefleXion booth during exhibit hours<\/a>.<\/p>\n

\nAbout RefleXion Medical<\/b><\/p>\n

\nRefleXion<\/a> is a privately held theranostic oncology company located in Hayward, Calif., commercializing SCINTIX biology\u2011guided radiotherapy, a novel therapy that uses a single radiotracer injection to turn cancer cells into real\u2011time biological beacons to guide external\u2011beam radiotherapy. SCINTIX therapy is FDA\u2011cleared for FDG\u2011guided treatment of lung and bone tumors, including metastases, and is under investigation for additional tracers and indications. The RefleXion X1 platform is also cleared for conventional image\u2011guided radiotherapy for solid tumors anywhere in the body. For more information, visit www.reflexion.com<\/a>.<\/p>\n\n\n\n
________________________________<\/td>\n<\/tr>\n
1<\/sup> The future, next-generation, platform is in development. It has not been approved by FDA, and its safety and effectiveness has not been established. It is not available for sale.<\/b><\/td>\n<\/tr>\n<\/table>\n

\n\u00a0<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/strong>
contact@reflexion.com<\/a>
+1-650-239-9070<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HAYWARD, Calif.–(BUSINESS WIRE)–#BGRT—RefleXion Medical, an external\u2011beam theranostic oncology company, today announced first results from the PREMIER Registry (NCT05406167) evaluating its SCINTIX\u00ae biology-guided radiotherapy, or BgRT, platform in patients with lung and bone tumors. The findings, presented at the 2025 ASTRO Annual Meeting, showed local control of 100 percent at nine months post-treatment with no reported … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61949","6":"format-standard","7":"category-industry"},"yoast_head":"\nRefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HAYWARD, Calif.–(BUSINESS WIRE)–#BGRT—RefleXion Medical, an external\u2011beam theranostic oncology company, today announced first results from the PREMIER Registry (NCT05406167) evaluating its SCINTIX\u00ae biology-guided radiotherapy, or BgRT, platform in patients with lung and bone tumors. The findings, presented at the 2025 ASTRO Annual Meeting, showed local control of 100 percent at nine months post-treatment with no reported ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-30T14:06:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250930703119\/en\/2594701\/22\/X1_PET_Emissions.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors\",\"datePublished\":\"2025-09-30T14:06:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/\"},\"wordCount\":500,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250930703119\\\/en\\\/2594701\\\/22\\\/X1_PET_Emissions.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/\",\"name\":\"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250930703119\\\/en\\\/2594701\\\/22\\\/X1_PET_Emissions.jpg\",\"datePublished\":\"2025-09-30T14:06:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250930703119\\\/en\\\/2594701\\\/22\\\/X1_PET_Emissions.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250930703119\\\/en\\\/2594701\\\/22\\\/X1_PET_Emissions.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/","og_locale":"en_US","og_type":"article","og_title":"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors - Pharma Trend","og_description":"HAYWARD, Calif.–(BUSINESS WIRE)–#BGRT—RefleXion Medical, an external\u2011beam theranostic oncology company, today announced first results from the PREMIER Registry (NCT05406167) evaluating its SCINTIX\u00ae biology-guided radiotherapy, or BgRT, platform in patients with lung and bone tumors. The findings, presented at the 2025 ASTRO Annual Meeting, showed local control of 100 percent at nine months post-treatment with no reported ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/","og_site_name":"Pharma Trend","article_published_time":"2025-09-30T14:06:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250930703119\/en\/2594701\/22\/X1_PET_Emissions.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors","datePublished":"2025-09-30T14:06:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/"},"wordCount":500,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250930703119\/en\/2594701\/22\/X1_PET_Emissions.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/","url":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/","name":"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250930703119\/en\/2594701\/22\/X1_PET_Emissions.jpg","datePublished":"2025-09-30T14:06:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250930703119\/en\/2594701\/22\/X1_PET_Emissions.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250930703119\/en\/2594701\/22\/X1_PET_Emissions.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/reflexion-medical-announces-first-clinical-outcomes-for-scintix-therapy-in-lung-and-bone-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61949"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61949\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}